Literature DB >> 22105373

Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases.

P Zarogoulidis1, N Papanas, I Kioumis, E Chatzaki, E Maltezos, K Zarogoulidis.   

Abstract

BACKGROUND: Macrolides have long been recognised to exert immunomodulary and anti-inflammatory actions. They are able to suppress the "cytokine storm" of inflammation and to confer an additional clinical benefit through their immunomodulatory properties.
METHODS: A search of electronic journal articles was performed using combinations of the following keywords: macrolides, COPD, asthma, bronchitis, bronchiolitis obliterans, cystic fibrosis, immunomodulation, anti-inflammatory effect, diabetes, side effects and systemic diseases.
RESULTS: Macrolide effects are time- and dose-dependent, and the mechanisms underlying these effects remain incompletely understood. Both in vitro and in vivo studies have provided ample evidence of their immunomodulary and anti-inflammatory actions. Importantly, this class of antibiotics is efficacious with respect to controlling exacerbations of underlying respiratory problems, such as cystic fibrosis, asthma, bronchiectasis, panbrochiolitis and cryptogenic organising pneumonia. Macrolides have also been reported to reduce airway hyper-responsiveness and improve pulmonary function.
CONCLUSION: This review provides an overview on the properties of macrolides (erythromycin, clarithromycin, roxithromycin, azithromycin), their efficacy in various respiratory diseases and their adverse effects.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22105373     DOI: 10.1007/s00228-011-1161-x

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  317 in total

1.  Successful treatment of a case with rapidly progressive Bronchiolitis obliterans organizing pneumonia (BOOP) using cyclosporin A and corticosteroid.

Authors:  Daizo Koinuma; Makoto Miki; Masahito Ebina; Minoru Tahara; Koichi Hagiwara; Takashi Kondo; Yoshio Taguchi; Toshihiro Nukiwa
Journal:  Intern Med       Date:  2002-01       Impact factor: 1.271

Review 2.  Host modulation with tetracyclines and their chemically modified analogues.

Authors:  L M Golub; K Suomalainen; T Sorsa
Journal:  Curr Opin Dent       Date:  1992-03

3.  Ototoxicity with azithromycin.

Authors:  M R Wallace; L K Miller; M T Nguyen; A R Shields
Journal:  Lancet       Date:  1994-01-22       Impact factor: 79.321

4.  Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD.

Authors:  M Miravitlles; C Espinosa; E Fernández-Laso; J A Martos; J A Maldonado; M Gallego
Journal:  Chest       Date:  1999-07       Impact factor: 9.410

5.  Azithromycin is associated with increased survival in lung transplant recipients with bronchiolitis obliterans syndrome.

Authors:  Raksha Jain; Ramsey R Hachem; Matthew R Morrell; Elbert P Trulock; Murali M Chakinala; Roger D Yusen; Howard J Huang; Thalachallour Mohanakumar; G Alexander Patterson; Michael J Walter
Journal:  J Heart Lung Transplant       Date:  2010-02-04       Impact factor: 10.247

Review 6.  Macrolide antibiotics as immunomodulatory medications: proposed mechanisms of action.

Authors:  Masaharu Shinkai; Markus O Henke; Bruce K Rubin
Journal:  Pharmacol Ther       Date:  2007-12-15       Impact factor: 12.310

7.  Erythromycin ototoxicity: analysis and conclusions based on 22 case reports.

Authors:  R C Haydon; J W Thelin; W E Davis
Journal:  Otolaryngol Head Neck Surg       Date:  1984-12       Impact factor: 3.497

8.  Macrolide resistance of Staphylococcus aureus and Haemophilus species associated with long-term azithromycin use in cystic fibrosis.

Authors:  Sonja J Phaff; Harm A W M Tiddens; Henry A Verbrugh; Alewijn Ott
Journal:  J Antimicrob Chemother       Date:  2006-02-09       Impact factor: 5.790

Review 9.  Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes.

Authors:  Françoise Van Bambeke; Paul M Tulkens
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

10.  Systems-level comparison of host-responses elicited by avian H5N1 and seasonal H1N1 influenza viruses in primary human macrophages.

Authors:  Suki M Y Lee; Jennifer L Gardy; C Y Cheung; Timothy K W Cheung; Kenrie P Y Hui; Nancy Y Ip; Y Guan; Robert E W Hancock; J S Malik Peiris
Journal:  PLoS One       Date:  2009-12-14       Impact factor: 3.240

View more
  91 in total

1.  Effect of azithromycin on systemic markers of inflammation in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa.

Authors:  Felix Ratjen; Lisa Saiman; Nicole Mayer-Hamblett; Larry C Lands; Margaret Kloster; Valeria Thompson; Peggy Emmett; Bruce Marshall; Frank Accurso; Scott Sagel; Michael Anstead
Journal:  Chest       Date:  2012-11       Impact factor: 9.410

2.  Inflammation and Oxidation Biomarkers in Patients with Cystic Fibrosis: The Influence of Azithromycin.

Authors:  Casilda Olveira; Alicia Padilla; Antonio Dorado; Victoria Contreras; Eduardo Garcia-Fuentes; Elehazara Rubio-Martin; Nuria Porras; Esperanza Doña; Ana Carmona; Gabriel Olveira
Journal:  Eurasian J Med       Date:  2017-06

3.  PharmGKB summary: Macrolide antibiotic pathway, pharmacokinetics/pharmacodynamics.

Authors:  Alison E Fohner; Alex Sparreboom; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2017-04       Impact factor: 2.089

4.  Macrolides for acute lung injury.

Authors:  Michael J Noto; Arthur P Wheeler
Journal:  Chest       Date:  2012-05       Impact factor: 9.410

5.  Psychotropic effects of antimicrobials and immune modulation by psychotropics: implications for neuroimmune disorders.

Authors:  Demian Obregon; Ellisa Carla Parker-Athill; Jun Tan; Tanya Murphy
Journal:  Neuropsychiatry (London)       Date:  2012-08

6.  Blood, tissue, and intracellular concentrations of azithromycin during and after end of therapy.

Authors:  P Matzneller; S Krasniqi; M Kinzig; F Sörgel; S Hüttner; E Lackner; M Müller; M Zeitlinger
Journal:  Antimicrob Agents Chemother       Date:  2013-01-28       Impact factor: 5.191

7.  Lessons learned from 2 decades of CAP therapy data: ways to improve patient management.

Authors:  Michael T Bender; Michael S Niederman
Journal:  J Thorac Dis       Date:  2016-06       Impact factor: 2.895

8.  Effect of Qingfei Mixture () on pediatric mycoplasma pneumoniae pneumonia with phlegm heat obstructing Fei (Lung) syndrome.

Authors:  Ai-Jun Yang; Kun Xi; Yan-Qing Yao; Ying-Xue Ding; Li-Jun Yang; Hong Cui
Journal:  Chin J Integr Med       Date:  2017-09-02       Impact factor: 1.978

Review 9.  Cystic Fibrosis: Microbiology and Host Response.

Authors:  Edith T Zemanick; Lucas R Hoffman
Journal:  Pediatr Clin North Am       Date:  2016-08       Impact factor: 3.278

10.  Linezolid and vancomycin decrease the therapeutic effect of methylene blue-photodynamic therapy in a mouse model of MRSA bacterial arthritis.

Authors:  Masamitsu Tanaka; Pawel Mroz; Tianhong Dai; Liyi Huang; Yuji Morimoto; Manabu Kinoshita; Yasuo Yoshihara; Nariyoshi Shinomiya; Shuhji Seki; Koichi Nemoto; Michael R Hamblin
Journal:  Photochem Photobiol       Date:  2013-02-19       Impact factor: 3.421

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.